Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
1(50.0%)
Phase 3
1(50.0%)
2Total
Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT00910819Completed

Tumour Registry Colorectal Cancer

Role: collaborator

NCT01351584Completed

Tumour Registry Breast Cancer

Role: collaborator

NCT00610012Completed

Tumor Registry of Advanced Renal Cell Carcinoma

Role: collaborator

NCT00868634Phase 3Completed

Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer

Role: collaborator

NCT00911222Completed

Epidemiological EMESIS-Registry

Role: collaborator

NCT01238029Phase 1Terminated

Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer

Role: collaborator

All 6 trials loaded